Yongheng Chen

Journal of Hematology & Oncology · with Li · 2021–2022

A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from Yongheng Chen's perspective

Ordered by how strongly the researchers Yongheng Chen trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. (Journal of Clinical Investigation)
  2. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features (Proceedings of the National Academy of Sciences of the United States of America)
  3. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma (Modern Pathology)
  4. Structural and biochemical basis of apoptotic activation by Smac/DIABLO (Nature)
  5. The clonal and mutational evolution spectrum of primary triple-negative breast cancers (Nature)
  6. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial (Nature Medicine)
  7. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. (New England Journal of Medicine)
  8. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression (Clinical Cancer Research)
  9. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. (Journal of Clinical Investigation)
  10. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection (PLoS ONE)

Their papers